Caplin Point Laboratories
CAPLIPOINT · Pharma > Pharmaceuticals & Drugs · Chairman: C C Paarthipan · MD: Sridhar Ganesan · Listing date: June 23, 2014 · Employees: 1675 · Chennai · http://www.caplinpoint.net

Stock Price vs Company Growth
1d
0.5%
1w
3.3%
1m
8.8%
3m
21.3%
6m
66.6%
1y
29.1%
5y
27.7%
10y
27.1%
all
43.6%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 2,801 0.5%
2,287
2,874
Company Overview

Sales
2,287 Cr
Growth: 13.4%
Profit after Tax
665 Cr
Growth: 3.8%
Mid Cap
21,287 Cr
P/E: 32.1x
Industry P/E: 34.2x
Fundamentals

Sales (Cr) ₹ 2,287
Growth 13.4%
EBITDA 34.8%
P/S 9.3x
Dividend 0.3%
P/E 32.1x
Book Value ₹ 495
PEG Ratio 2.4x
ROE 19.2%
P/B 5.7x
Shareholding Pattern

Institutions
Promoters
P Vijayalakhsmi
23.64 %
Paarthipan C C
18.73 %
Ashok Gorkey Partheeban
11.96 %
Partheeban Vivek Siddarth
11.9 %
May India Property Private Limited
2.8 %
Others
Iepf
2.46 %
Visalatchi
2.22 %
Suresh Kumar Agarwal
1.32 %
Ashish Kacholia
1.16 %
Llp
0.7 %
Increase    Decrease    No change
Company Profile Detailed

Caplin Point Laboratories is engaged in manufacture of pharmaceuticals formulations. It is a fast-growing Indian pharmaceutical company with global reach, having a 100% export-oriented business. The company supplies a complete range of finished dosage forms. The company operates on a unique business model which predominantly caters to emerging markets of Latin America and Africa and a growing presence in regulated markets like the USA, Canada, Australia etc.
Investors (50)
Followers (28)